Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
How would you manage oligometastatic colon cancer with a resected primary and liver metastasis found to be MSI-H?
Would you prioritize chemotherapy or immunotherapy for curative intent treatment?
Related Questions
Would you change treatment approach for rectal cancer with an associated intussusception?
Why does NCCN still not recommend using circulating tumor cells to guide adjuvant chemotherapy in stage II colon cancer when colon cancer experts are currently embracing the practice?
If using GCSF with mFOLFIRINOX, would you ever use it during day 1?
How do you approach an isolated metastasis to left supraclavicular node in rectal cancer treated with TNT with FOLFOX regimen followed by long course radiation?
Would you offer surgery for an MSI-H pancreatic adenocarcinoma who had deep response to pembrolizumab?
How would you approach the management of a patient with stage IIIA lung adenocarcinoma and multifocal hepatocellular carcinoma with Child-Pugh A cirrhosis?
Do you modify the dose of Naliri in Nalirifox for patient that are heterozygous for UGT1A1 mutations?
Are there any data (retrospective or otherwise) on the watch and wait approach in patients who achieve cCR after CRT without consolidation chemotherapy?
What second-line therapy would you offer a patient with metastatic colon cancer with HER2 IHC 3+ amplification and KRAS G12D mutation whose disease progressed on FOLFOX?
Would you consider adding encorafenib + cetuximab to adjuvant mFOLFOX for a patient with oligometastatic colon cancer with BRAF V600E mutation s/p metastasectomy and primary resection given the new data from the BREAKWATER trial?